CSTL Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 2.65% compared to Castle Biosciences's net margin of 16.64%. Castle Biosciences's return on equity of 1.49% beat Delcath Systems's return on equity of -251.36%.

Castle Biosciences has a consensus price target of $41.56, signalling upside risk potential of 49.91%. On the other hand Delcath Systems has an analysts' consensus of -- which suggests that it could grow by 88.13%. Given that Delcath Systems has higher upside potential than Castle Biosciences, analysts believe Delcath Systems is more attractive than Castle Biosciences.

Castle Biosciences has a beta of 0.919, which suggesting that the stock is 8.114% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.851, suggesting its less volatile than the S&P 500 by 14.882%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend.

Castle Biosciences quarterly revenues are $85.8M, which are larger than Delcath Systems quarterly revenues of $11.2M. Castle Biosciences's net income of $2.3M is higher than Delcath Systems's net income of $1.9M. Notably, Castle Biosciences's price-to-earnings ratio is 132.00x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 2.50x versus 13.59x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Exact Sciences has a net margin of 2.65% compared to Castle Biosciences's net margin of -5.4%. Castle Biosciences's return on equity of 1.49% beat Exact Sciences's return on equity of -6.77%.

Castle Biosciences has a consensus price target of $41.56, signalling upside risk potential of 49.91%. On the other hand Exact Sciences has an analysts' consensus of $71.86 which suggests that it could grow by 23.66%. Given that Castle Biosciences has higher upside potential than Exact Sciences, analysts believe Castle Biosciences is more attractive than Exact Sciences.

Castle Biosciences has a beta of 0.919, which suggesting that the stock is 8.114% less volatile than S&P 500. In comparison Exact Sciences has a beta of 1.237, suggesting its more volatile than the S&P 500 by 23.719%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Exact Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Exact Sciences pays out -- of its earnings as a dividend.

Castle Biosciences quarterly revenues are $85.8M, which are smaller than Exact Sciences quarterly revenues of $708.7M. Castle Biosciences's net income of $2.3M is higher than Exact Sciences's net income of -$38.2M. Notably, Castle Biosciences's price-to-earnings ratio is 132.00x while Exact Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 2.50x versus 3.95x for Exact Sciences. Usually stocks with elevated PS ratios are considered overvalued.

Progyny has a net margin of 2.65% compared to Castle Biosciences's net margin of 3.64%. Castle Biosciences's return on equity of 1.49% beat Progyny's return on equity of 11.31%.

Castle Biosciences has a consensus price target of $41.56, signalling upside risk potential of 49.91%. On the other hand Progyny has an analysts' consensus of $30.22 which suggests that it could grow by 29.78%. Given that Castle Biosciences has higher upside potential than Progyny, analysts believe Castle Biosciences is more attractive than Progyny.

Castle Biosciences has a beta of 0.919, which suggesting that the stock is 8.114% less volatile than S&P 500. In comparison Progyny has a beta of 1.350, suggesting its more volatile than the S&P 500 by 34.952%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Progyny offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Progyny pays out -- of its earnings as a dividend.

Castle Biosciences quarterly revenues are $85.8M, which are smaller than Progyny quarterly revenues of $286.6M. Castle Biosciences's net income of $2.3M is lower than Progyny's net income of $10.4M. Notably, Castle Biosciences's price-to-earnings ratio is 132.00x while Progyny's PE ratio is 25.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 2.50x versus 1.26x for Progyny. Usually stocks with elevated PS ratios are considered overvalued.

Star Equity Holdings has a net margin of 2.65% compared to Castle Biosciences's net margin of -14.42%. Castle Biosciences's return on equity of 1.49% beat Star Equity Holdings's return on equity of -10.13%.

Castle Biosciences has a consensus price target of $41.56, signalling upside risk potential of 49.91%. On the other hand Star Equity Holdings has an analysts' consensus of -- which suggests that it could grow by 380.77%. Given that Star Equity Holdings has higher upside potential than Castle Biosciences, analysts believe Star Equity Holdings is more attractive than Castle Biosciences.

Castle Biosciences has a beta of 0.919, which suggesting that the stock is 8.114% less volatile than S&P 500. In comparison Star Equity Holdings has a beta of 0.080, suggesting its less volatile than the S&P 500 by 91.951%.

Castle Biosciences has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Star Equity Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Castle Biosciences pays -- of its earnings as a dividend. Star Equity Holdings pays out 7.62% of its earnings as a dividend. Star Equity Holdings's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Castle Biosciences quarterly revenues are $85.8M, which are larger than Star Equity Holdings quarterly revenues of $13.7M. Castle Biosciences's net income of $2.3M is higher than Star Equity Holdings's net income of -$2M. Notably, Castle Biosciences's price-to-earnings ratio is 132.00x while Star Equity Holdings's PE ratio is 0.70x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Castle Biosciences is 2.50x versus 0.13x for Star Equity Holdings. Usually stocks with elevated PS ratios are considered overvalued.